PAX3 and neoplasm: ENT as a single agent showed minimal antitumor activity in this embryonal model of RMS; however, in these fusion-negative (Pax3:Foxo1 non-expressing) mice, treatment with the combination of ENT plus VCR reduced tumor volume significantly (Fig. 1a, b).